Campaign for the early detection and prevention of diabetes from the Office of pharmacy.

-Is an initiative of the University of Granada, in collaboration with the Spanish society of community pharmacy (SEFAC), colleges of pharmacists and physicians and the support of the Club of the pharmacy of Almirall

-through one simple puncture on the finger you can detect cases of type 2 diabetes

– between 30 and 50 percent of people with diabetes in Spain they ignore his disease

Madrid, 2011-November in Spain, it is estimated that you between 30 and 50% of people with type 2 diabetes mellitus ignored her illness. Early detection and immediate treatment to achieve optimal glycaemic control in early stages of the disease gives a long-term benefit in reduction of morbidity and mortality that can be reversed in a major breakthrough in public health and health resources saving. Perform an opportunistic screening in the offices of pharmacy to identify people of high risk of developing diabetes is the goal of the campaign for early detection and prevention of diabetes: study DiabNow.

This study is an initiative of the research group in care pharmaceutical of the University of Granada (GIAF-UGR) which helped the Spanish society of community pharmacy (SEFAC) as well as pharmaceutical and medical schools in the five provinces where the campaign unfolds. All this with the support of the Club of the pharmacy of Almirall, entity collaborating with projects of innovation within the pharmaceutical profession emerged, as in this case, of the University level.

The campaign has just been put in place and involved more than 100 community pharmacists of the Spanish provinces of Granada, Cordoba, Huelva, Jaén and Ciudad Real. He is to sensitize the population with risk factors for developing diabetes about the importance of early detection. They may as well take preventive measures and receive tips and instructions to facilitate a healthy lifestyle in order to delay the onset and progression of the disease. Detection from the community of possible cases of diabetes type 2 hidden pharmacy will take place through a simple puncture on the finger. A drop of blood that will make it possible to quantify the value of glycosylated hemoglobin, which is a measure of chronic Hyperglycemia is thus removed.

Each pharmacist will get and will include a total of ten patients. You can participate in the study any person to go to the Office of the Pharmacy and, after collecting the personal data and check that it complies with the requirements, the pharmacy professional held a series of questions based on the test of risk of Diabetes from the American the Diabetes Association (ADA) which allows to quantify the risk. Patients who join a certain amount of points in the test will be selected to enter the DiabNow study and it will offer the possibility to perform the diagnostic test.

Type 2 diabetes

Diabetes is a disease characterized by a disturbance of the metabolism of the hydrates of carbon, defined by the chronic hyperglycemia and its long-term nature micro complications and macrovascular.

Type 2 diabetes accounts for 90-95% of all cases of diabetes. Characterized by a relative failure, rather than absolute, insulin and a resistance to its action. usually appear in adult life, over 40 years and does not always need treatment with insulin.

The risk of developing this form of diabetes increases with age, weight, and lack of exercise, being more frequent in obese hypertensive patients and people with high cholesterol.

Almirall

Almirall is an international pharmaceutical company based on innovation and committed to health. With headquarters in Barcelona (Spain), Almirall researches, develops, produces and sells drugs own r & d and licensing with the aim of improving the health and well-being of people.

The therapeutic areas in which concentrates its resources in research are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), gastrointestinal disorders, psoriasis and other skin complaints forms.

Almirall drugs are currently present in over 70 countries. It has direct presence in Europe and Latin America through 12 subsidiaries.